Please login to the form below

Not currently logged in

Mark Caulfield departs from Genomics England to take on CEO role at Barts Life Sciences

Caulfield served as chief scientist at Genomics England, working on the 100,000 Genomes Project

Mark Caulfield (pictured above) has departed from Genomics England to take on the chief executive officer role at Barts Life Sciences – a research and innovation partnership between Queen Mary University of London and Barts Health NHS Trust.

At Genomics England, Caulfield served as chief scientist – in 2013, he took leadership of the scientific oversight and delivery of the 100,000 Genomes Project.

He was awarded a knighthood in 2019 following the project’s ‘unprecedented success’, Genomics England said in a statement.

First launched in 2012, the 100,000 Genome Project had ambitious plans to map the genomes of NHS patients to deliver treatments for those with rare inherited diseases and cancer.

In 2018, Genomics England announced it had sequenced its 100,000th genome as part of the project.

At Barts Life Sciences, Caulfield will be responsible for the overall leadership and delivery of the programme and work alongside key stakeholders including Department of Health and Social Care, Office for Life Sciences, London Borough of Tower Hamlets, NHS Property Services and Barts Charity.

“I’m delighted to be joining Barts Life Sciences to lead the delivery of a thriving life sciences cluster at the heart of Whitechapel,” said Caulfield.

"By bringing together the NHS, academia, industry and health science organisations we will inspire, invent, and accelerate the adoption of cutting-edge medical innovations, that meet the needs of our local population and improve health for all,” he added.

Article by
Lucy Parsons

2nd July 2021

From: Research


Subscribe to our email news alerts


Add my company
Wave Healthcare Communications

Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...